Latest Breaking News On - Relationsroger pondel - Page 1 : comparemela.com

Lixte Biotechnology (LIXT) Prices 583K Share Offering at $6/sh

Lixte Biotechnology (LIXT) Prices 583K Share Offering at $6/sh
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkFlaurie bermanRelationsroger pondelExchange commissionSecurities exchangeBiotechnology holdings incLixte biotechnology holdings incA gp alliance global partnersPondelwilkinson incAlliance global partnersSecurities actSecurities exchange actUnited states securitiesInvestor relationsroger pondelLixte biotechnology holdings

Lixte Biotechnology Holdings, Inc (LIXT) Announces 1:10 Reverse Stock Split

Lixte Biotechnology Holdings, Inc (LIXT) Announces 1:10 Reverse Stock Split
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFlaurie bermanRelationsroger pondelPondelwilkinson incCompany nasdaqExchange commissionLixte biotechnology holdings incCompany board of directorsSecurities exchangeExchange commission onComputershare trust companyBiotechnology holdings incNasdaq capital marketNasdaq capitalTrust companySecurities act

LIXTE BIOTECHNOLOGY HOLDINGS, INC REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELS

LIXTE BIOTECHNOLOGY HOLDINGS, INC REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELS
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNoord hollandFlaurie bermanRelationsroger pondelJohns kovachMatheus henrique diasRene bernardsExchange commissionCompany nasdaqBiotechnology holdings incSecurities exchangeNetherlands cancer instituteLixte biotechnology holdings incPondelwilkinson incWall streetProfessor rene bernards